Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) combined with endocrine therapy are the preferred choice for first-line treatment of patients with HR<sup>+</sup>/HER2<sup>-</sup> locally advanced/metastatic breast cancer (aBC). This evidence concerns the gene ERBB2 and aneurysmal bone cyst.